T-Box Transcription Factors in Development and Cancer

T-box transcription factors constitute an evolutionarily conserved family defined by a characteristic T-box DNA-binding domain that directs gene expression programmes crucial for embryonic patterning, organogenesis and lineage specification. Members such as TBX2, TBX3, TBX5 and TBX15 regulate cell proliferation, differentiation and apoptosis across diverse tissues including the heart, limbs, mammary glands and central nervous system. Their activity integrates signals from key developmental pathways – notably Wnt, FGF and BMP – to balance growth and morphogenesis. Mutations or dosage imbalances of T-box genes underlie congenital syndromes such as ulnar–mammary and Holt–Oram, illustrating their vital role in early development. In adult tissues, aberrant reactivation or overexpression of T-box proteins is increasingly recognised as a driver of malignancy. Oncogenic kinases can co-opt developmental programmes by stabilising T-box factors, promoting epithelial dedifferentiation, invasion and resistance to cell death. These dual roles underscore the importance of dissecting the molecular mechanisms that distinguish physiological from pathological T-box activity and pave the way for translating developmental insights into targeted cancer therapies.

Research from Nature Portfolio

Recent studies have shown that proteostatic control of TBX3 is central to BRAF/MAPK-driven tumourigenesis. Oncogenic BRAF signalling upregulates the deubiquitinase USP15, which stabilises TBX3 and re-initiates embryonic gene programmes, driving epithelial dedifferentiation and tumour formation. Genetic ablation of USP15 or TBX3 restores differentiation and impairs tumour growth, highlighting the USP15-TBX3 axis as a promising therapeutic target. In parallel, investigation of TBX15 in human gliomas has revealed its overexpression to correlate with high tumour grade, poor patient survival and an immunosuppressive microenvironment. Elevated TBX15 supports recruitment of regulatory immune cells and associates with downregulation of antitumour pathways, suggesting its utility as a prognostic marker and a modulator of tumour–immune crosstalk.

T-Box Transcription Factors in Development and Cancer publication trend

The graph below shows the total number of articles in t-box transcription factors in development and cancer across all publications each year (not limited to Nature Index journals).

Technical terms

T-box domain: Conserved DNA-binding motif characteristic of T-Box transcription factors.

Organogenesis: Embryonic process by which organs form and acquire specialised structures.

Proteostatic mechanism: Cellular processes that maintain protein stability and regulate degradation.

Epithelial–mesenchymal transition (EMT): Biological programme in which epithelial cells acquire mesenchymal characteristics, enhancing motility and invasiveness.

Tumour immune microenvironment: Cellular and molecular context within a tumour that shapes immune cell recruitment and function.

References

1. Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis. Nature Communications (2024).
2. Context-dependent T-BOX transcription factor family: from biology to targeted therapy. Cell Communication and Signaling (2024).
3. The overexpression and clinical significance of TBX15 in human gliomas. Scientific Reports (2023).
4. An inherited TBX3 alteration in a prenatal case of ulnar‐mammary syndrome: Clinical assessment and functional characterization in Drosophila melanogaster. Journal of Cellular Physiology (2024).
5. Novel HDAC5-interacting motifs of Tbx3 are essential for the suppression of E-cadherin expression and for the promotion of metastasis in hepatocellular carcinoma. Signal Transduction and Targeted Therapy (2018).